全文获取类型
收费全文 | 435篇 |
免费 | 16篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 13篇 |
妇产科学 | 6篇 |
基础医学 | 37篇 |
口腔科学 | 5篇 |
临床医学 | 44篇 |
内科学 | 95篇 |
皮肤病学 | 10篇 |
神经病学 | 4篇 |
特种医学 | 154篇 |
外科学 | 34篇 |
综合类 | 2篇 |
预防医学 | 13篇 |
眼科学 | 9篇 |
药学 | 21篇 |
肿瘤学 | 11篇 |
出版年
2022年 | 4篇 |
2021年 | 7篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 16篇 |
2016年 | 6篇 |
2015年 | 3篇 |
2014年 | 3篇 |
2013年 | 16篇 |
2012年 | 5篇 |
2011年 | 7篇 |
2010年 | 6篇 |
2009年 | 12篇 |
2008年 | 8篇 |
2007年 | 12篇 |
2006年 | 16篇 |
2005年 | 11篇 |
2004年 | 5篇 |
2003年 | 2篇 |
2002年 | 11篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 5篇 |
1998年 | 16篇 |
1997年 | 23篇 |
1996年 | 22篇 |
1995年 | 14篇 |
1994年 | 22篇 |
1993年 | 13篇 |
1992年 | 4篇 |
1991年 | 9篇 |
1990年 | 5篇 |
1989年 | 22篇 |
1988年 | 18篇 |
1987年 | 10篇 |
1986年 | 19篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 4篇 |
1982年 | 12篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 6篇 |
1975年 | 6篇 |
1971年 | 2篇 |
1961年 | 1篇 |
1935年 | 1篇 |
排序方式: 共有458条查询结果,搜索用时 0 毫秒
1.
Hillmann JS; Mesgarzadeh M; Revesz G; Bonakdarpour A; Clancy M; Betz RR 《Radiology》1987,165(3):769-773
Proximal femoral focal deficiency, an uncommon congenital anomaly, necessitates early radiologic classification for surgical planning and treatment. Objective radiographic criteria, including femoral length index, acetabular depth index, acetabular angle index, and shape of the proximal femur were determined in 49 patients before cartilaginous ossification of the femoral capital epiphysis; final classification was based on follow-up radiographs or findings at arthrography or surgery. These parameters were analyzed to determine the accuracy and contributions of each in classification. Correct classification into one of three groups was possible in 86% of cases with use of three of the parameters: femoral length index, acetabular depth index, and shape of the proximal femur. The acetabular angle was found to contribute insignificantly to classification. Magnetic resonance imaging, used in only one case, depicted the nonossified cartilaginous femoral capital epiphysis, thus obviating the need for invasive diagnostic procedures and facilitating early classification. 相似文献
2.
3.
4.
5.
6.
Life expectancy in British Marfan syndrome populations 总被引:2,自引:0,他引:2
JR Gray AB Bridges RR West L. McLeish AG Stuart JCS Dean MEM Porteous M. Boxer SJ Davies 《Clinical genetics》1998,54(2):124-128
A total of 206 patients with Marfan syndrome were ascertained throughout genetic clinics in Wales and Scotland during the period 1970–1990. There were 45 deaths representing 22% of the cohort. Mean age at death was 45.3 ± 16.5 years. 50% median cumulative survival in the total cohort (n = 206) was 53 years for males and 72 years for females. Multivariate analysis confirmed severity as the best independent indicator of survival. These findings and survival curves will assist in the counselling of British families and individuals with Marfan syndrome. 相似文献
7.
8.
Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease 总被引:1,自引:0,他引:1
S. Krähenbühl P. Grass A. Surve K. Kutz J. Reichen 《European journal of clinical pharmacology》1993,45(3):247-253
Summary The pharmacokinetics and haemodynamic effects of orally administered spirapril, a novel angiotensinconverting enzyme (ACE) inhibitor, have been investigated in patients with liver cirrhosis (n=10), in patients with chronic, non-cirrhotic liver disease (n=8) and in a control group of healthy subjects (n=16).The absorption and elimination of spirapril did not differ between patients with liver disease and control subjects. In contrast, the bioavailability of spiraprilat, the metabolite responsible for the pharmacological action of spirapril, was significantly reduced in patients (AUC 820 g·h·l–1, 923 g·h·l–1 and 1300 g·h·l–1 in patients with cirrhosis, patients with non-cirrhotic liver disease and in healthy subjects, respectively.Compared to healthy subjects, cirrhotic patients had a reduced rate constant of spiraprilat formation (1.10 h–1 in patients vs. 2.00 h–1 in control subjects) while the elimination half-life of spiraprilat was not different. The effect of spirapril on diastolic blood pressure was decreased in patients with chronic liver disease as compared to the controls.Thus, the pharmacokinetics of spirapril was unchanged in patients with different types of liver disease, including cirrhosis. However, the bioavailability of spiraprilat and hypotensive effect of spirapril were reduced in patients. 相似文献
9.
In an open-label, randomized trial using a 3 x 3 Latin square design, single doses of 24 mg of the ACE inhibitor spirapril, or 50 mg hydrochlorothiazide, or their combination were given to 18 healthy male volunteers. No alteration in the area under plasma drug concentration curve (AUC), peak plasma level, time to peak level, or elimination half-life was detected for hydrochlorothiazide, spirapril, or its active metabolite, spiraprilat, during combination therapy. It was concluded that there was no significant effect of spirapril on single-dose kinetics of hydrochlorothiazide, nor of hydrochlorothiazide on single-dose kinetics of spirapril. Significant reductions in systolic blood pressure were noted 2--6 h after either spirapril or combination treatment, but no evidence of any synergistic effect of single-dose effects on blood pressure was seen during combination therapy. 相似文献
10.